Search PubMed⌕ Search

Biomedical subjects

M Baccarani

Publications and source records attributed to M Baccarani.

At least 217 records · Page 12Linked to original sources
PubMed1979

Growth patterns, cell composition, and mitotic activity of granulocytic aggregates developing in methyl cellulose from human normal marrow cells.

Marrow cells from five normal healthy subjects were cultured in methyl cellulose with and without leucocyte conditioned medium. Cultures were examined daily from day 3 to day 14 for the number of granulocytic aggregates and for their cell composition and mitotic activity. Aggregates of different size (small and large clusters, small and large colonies) displayed four distinct and characteristic patterns of growth. Unidentifiable blast cells were very rare throughout culture. The average proportion of recognizable granulocyte precursors (promyelocytes and myelocytes) (PMC + MC) declined during culture from 60% to 34%. There was a negative correlation between the size of the aggregates and their PMC + MC content, but on any day of culture some aggregates consisted mainly or uniquely of PMC + MC, while some others consisted mainly or uniquely of non-proliferating granulocytes. The mitotic index of PMC + MC was much higher than the one previously determined in vivo, and was significantly higher in large colonies than in other aggregates. These results are consistent with the recent demonstration of different CFU-C (sub)populations. It is suggested that differentiation of the aggregates according to their size and kinetics, coupled with cytological examination, can provide a more refined assessment of the assay, which could be useful for further comparison of normal, abnormal, and leukaemic granulocytopoiesis.

Adult↗
PubMed1979

Congenital dyserythropoietic anemia type II: serologic and morphologic family study.

A 29-year old woman with a history of chronic anemia, jaundice, and splenectomy was found to have congenital dyserythropoietic anemia type II (CDA II), based on the following: marrow erythroid hyperplasia, abundance of binucleated erythroblasts, electron microscopic evidence of double membranes lining the cell membrane, erythrocyte lysis in the acidified serum test, erythrocyte agglutination and lysis by anti-i antibodies. Three healthy relatives (mother, father, and brother) of the patient had marrow erythroid hyperplasia and a percentage of binucleated erythroblasts that was higher than normal. A structural alteration of the nuclear membrane was detected in some of their erythroblasts. Furthermore, the erythrocytes of the father and the brother were agglutinated by anti-i antibodies. This observation is consistent with a recessive mechanism of inheritance, and suggests that heterozygosity for CDA II can be somatically expressed at different levels.

Adult↗
PubMed1978

The relevance of extramedullary hemopoiesis to the staging of chronic myeloid leukemia.

In chronic myeloid leukemia (CML) the spleen and the liver can lodge, trap and release a high proportion of leukemic cells, and are active sites of (leukemic) hemopoiesis throughout the disease. Evidence is provided that spleen and liver volume have a prognostic value, and that marrow, spleen, and liver differ as to cell composition, cell kinetic patterns, functional cell characters, and cell karyotype. In the majority of the patients, extramedullary hemopoiesis seems to be more abnormal than marrow hemopoiesis, supporting the hypothesis that spleen and/or liver can play an important role in the evolution of CML towards the blastic metamorphosis. However, present information on extramedullary hemopoiesis does not allow to identify specific patterns and to establish its relevance to the course of the disease.

Bone Marrow↗
PubMed1978

Effect of early splenectomy and cyclic acute leukemia-like chemotherapy on the course of chronic myeloid leukemia.

This report provides information on the progress of two trials by the Italian Cooperative Study on Chronic Myeloid Leukemia (CML). Both trials were designed in order to test the effect of early splenectomy and of cyclic administration of either arabinosyl cytosine and vincristine plus prednisone, or arabinosyl cytosine plus thioguanine plus daunomycin, on the course of CML and on the survival. A preliminary analysis, performed on September, 1977, suggests that neither splenectomy nor the chemotherapy scheduled have resulted in a significant decrease of the rate of blastic transformation of CML, during the first 2 to 3 years from diagnosis.

Adult↗
PubMed1978

Therapy of chronic myeloid leukemia (CML): interim report on protocols CML/73 and CML/74.

Current therapies of chronic myeloid leukemia (CML) do not prevent the progression of the disease towards blastic metamorphosis, and have not resulted in a remarkable prolongation of survival. Splenectomy was proposed with the aim of removing a part of the tumor without cytotoxics and of removing a potentially privileged pool of malignant blast cells. Acute leukemia-like chemotherapy was proposed with the aim of eradicating or better controlling the highly malignant subclones that emerge during the chronic phase. A preliminary analysis of 2 clinical trials these therapeutic measures, suggests that splenectomy does not modify the rate of blastic transformation, during the first 2 to 3 years from diagnosis. Also the rate of blastic transformation is similar for patients receiving hydroxyurea at first, and arabinosyl cytosine (ARA-C), vincristine (VCR) and prednisone (P) thereafter, as for patients receiving from the clinical onset of CML a more intensive chemotherapy with ARA-C, thioguanine (TG) and daunomycin (DAUNO), but not VCR + P.

Antineoplastic Agents↗
PubMed1978

Clinical contribution to the knowledge of hemopoietic dysplasias: long-term follow-up of 13 patients with refractory anemia.

Refractory anemia (RA) is an hematologic disorder at risk of developing into a malignancy (hemopoietic dysplasia). Information on hemopoietic dysplasias is useful for sharpening the appropriate diagnostic criteria and for the search of an appropriate therapy. Moreover, hemopoietic dysplasias provide an interesting opportunity, in humans, for studying a developing leukemia, or a disease situated at the boundary of leukemia. This paper reports on the evolution of RA in 13 patients followed up more than 2 years, through clinical observation, blood and marrow examination, and karyotype analysis. 4 of these 13 patients developed acute or subacute myeloid leukemia. An additional patient died because of severe thrombocytopenia. In these 5 patients, dyserythropoiesis was accompanied by thrombocytopenia, marrow myeloblastosis, and nonrandom chromosome abnormalities.

Aged↗
PubMed1978

5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas.

Five courses of a combination chemotherapy regimen with methotrexate, cyclophosphamide (Endoxan), and vincristine were given to 64 patients, 37 with lymphocytic lymphoma (LL) and 27 with histocytic lymphoma (HL). Eighteen of the 37 patients with LL (48%) achieved a complete remission (CR); 12 of these 18 patients have been in CR for 20--58 months. Among the complete responders only two died. Twenty-two of the 27 patients with HL (81%) achieved CR and 12 of these patients are still in CR. Ten of the complete responders have been relapse-free for 24--70 months and five have been relapse-free for greater than 60 months. Clinical and hematologic tolerance was such that the interval between each course had to be prolonged in only three of the 64 patients and, with the exception of vincristine, the dosages were not reduced.

Adolescent↗
PubMed1977

Acute promyelocytic leukemia: results of therapy and analysis of 13 cases.

Acute promyelocytic leukemia (APL) was diagnosed in 13 of 84 adult patients (15.4%) with acute myeloid leukemia (AML) first admitted between 1972 and 1976. All patients had clinical and/or laboratory evidence of defibrination syndrome. Four patients died of cerebral hemorrhage within 2 days of admission. Two patients died of generalized infection on days 7, and 16, respectively, after admission. The remaining 7 patients (54%) underwent complete remission (CR) with daunomycin, arabinosyl cytosine, and adriamycin. All patients received massive platelet transfusion, no heparin, and no granulocyte transfusion. CR was more frequent in patients with a very low blast cell count and a fibrinogen level higher than 100 mg/100 ml. Median survival of these seven CR patients with APL is similar (15 months) to that of CR patients with other types of AML treated at the same institution during the same period.

Adolescent↗